Motixafortide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Motixafortide. Educational only — not medical advice.
Labeled uses
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
Source: FDA labeling via NIH DailyMed (set f7cdc584…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.